Skye Bioscience to Participate in SXSW Session on Obesity
Rhea-AI Summary
Skye Bioscience (Nasdaq: SKYE), a clinical-stage biopharmaceutical company specializing in obesity and metabolic health disorders treatments, has announced its participation in a significant South by Southwest (SXSW) panel discussion.
CEO Punit Dhillon will join a panel session titled 'Weighing in on Weight Loss Medicine' which will explore the future of obesity management beyond GLP-1 drugs. The session is scheduled for Monday, March 10, 2025, from 10:00 AM to 11:00 AM CT in Austin, TX.
SXSW, a renowned platform that combines technology, film, music, education, and culture, is known for promoting innovation and collaboration. The conference features dedicated tracks on health and medtech, showcasing breakthrough developments and innovative ideas in life sciences.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SKYE declined 3.02%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel session exploring the future of obesity management beyond GLP-1 drugs.
SXSW Conference Panel Session: "Weighing in on Weight Loss Medicine"
- Focus: The
- Date: Monday, March 10, 2025
- Time: 10:00 AM - 11:00 AM CT
- Location: Austin, TX
SXSW is renowned for converging technology, film, music, education, and culture. Known for fostering innovation and collaboration, SXSW provides a global platform for thought leaders, industry experts, and visionaries to share insights, explore emerging trends, and drive meaningful conversations. Its dedicated tracks on health and medtech spotlight groundbreaking advancements and transformative ideas shaping the future of life sciences.
About Skye Bioscience
Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.
CONTACTS
Investor Relations
ir@skyebioscience.com
(858) 410-0266
LifeSci Advisors, Mike Moyer
mmoyer@lifesciadvisors.com
(617) 308-4306
Media Inquiries
LifeSci Communications, Michael Fitzhugh
mfitzhugh@lifescicomms.com
(628) 234-3889
FAQ
What is the focus of Skye Bioscience's SXSW 2025 panel discussion?
When and where is Skye Bioscience's SXSW 2025 panel session scheduled?
What therapeutic areas does SKYE focus on as a clinical-stage company?
Which Skye Bioscience executive will be speaking at SXSW 2025?
